FDA Issues 5-Point Action Plan For Artificial Intelligence/Machine Learning-Based SaMD
Executive Summary
A new guidance document and a promise to hold a public workshop are just two commitments made by the US agency in a 12 January action plan aimed at AI/ML-based software as a medical device.
You may also be interested in...
FDA Panel Meeting To Focus On AI/ML Device Labeling, Transparency
The US agency will host an October public workshop to get stakeholder input in developing a much-anticipated artificial intelligence/machine learning draft guidance.
Analyst Insight: Top 2021 Health Care Trends On Display At RSNA
A confluence of factors promoting the rapid adoption of health care AI is expected to make 2021 a pivotal year for the technology, as demonstrated by product launches at RSNA 2020.
GOP Senator Wants Time Frame And Other Details On FDA’s AI/ML Action Plan
US Sen. Bill Cassidy says he wants more details about the FDA’s plans to regulate AI/ML medical software, including a time frame for publishing guidance documents.